Insulators combined with the erythroid-specific IHK promoter could potentially confer long-term therapeutic levels of hemoglobin for the treatment of sickle cell disease, β-thalassemia, and other hemoglobinopathies utilizing CD34+ cells. Here, CD34 is linked to hemoglobinopathy.